World-first legislation backs decentralised manufacturing
The landmark regulation establishes a future where highly personalised treatments are part of routine care, says MHRA’s Chief Executive.
List view / Grid view
The landmark regulation establishes a future where highly personalised treatments are part of routine care, says MHRA’s Chief Executive.
While a focus on accelerating access for innovative medicines has been welcomed, industry representatives caution that current system infrastructure could hinder the plans proposed by the UK Government.
The new UK strategy represents a milestone for enhancing international competitiveness and puts into motion the upcoming Life Sciences Sector Plan.
The UK Government’s £86 billion announcement will help strengthen innovation and economic growth in key sectors including life sciences.
BioNTech’s commitment aligns with the UK Government’s Plan for Change, which involves accelerating growth of the pharmaceutical industry.
The announcement supports the UK Government’s broader plans for reformation of longer-term funding for the research and development sector.
This article offers key industry perspectives on the UK government’s recent immigration whitepaper and highlights the challenge of balancing economic growth and attracting skilled talent.
The multi-billion-pound deal provides a boost to the UK’s economy, however it lacks provision to aid the country’s growth ambitions, states the ABPI.
Immigration law experts from Fragomen LLP discuss currently challenges in the UK’s visa system and propose recommendations for attracting science and technology talent that support the country’s competitiveness.
A major overhaul of the UK’s Apprenticeship Levy promises to deliver greater flexibility for pharmaceutical workforce training, helping to address critical skills shortages.
Under growing global competition, this development highlights potential challenges for the UK to uphold large-scale pharmaceutical investments.
The announcement follows the completed construction of Moderna’s MITC and progress in its long-term partnership with the UK government.
For a strong 2025, dealmaking should be central to the life sciences strategy, says EY’s annual M&A report.
The amended regulatory framework will foster clinical trial design innovation and provide UK life sciences with faster trial approvals.
The joint agreement between two key global players in life sciences, the UK and Switzerland, marks a long-term commitment to strengthening research in the sector.